Silk Road Medical has announced the milestone of more than 100,000 transcarotid artery revascularisation (TCAR) procedures having been performed to date.
“A growing number of patients come to us looking for a solution that is minimally invasive and requires less downtime so they can get back to their daily lives,” said Gregg Landis (Northwell Health, New York, USA). “It’s incredible that Silk Road was able to not only address that need by creating the TCAR procedure, but also achieve such widespread adoption in a short period of time. TCAR has transformed the way we approach treating carotid artery disease while consistently delivering positive patient outcomes.”
Silk Road claims in a recent press release that, since its inception, the company has worked diligently to reduce the risk of stroke during treatment of carotid artery disease through innovative technology and minimally invasive techniques.
Silk Road is credited with pioneering the TCAR procedure and building the Enroute transcarotid neuroprotection system (Enroute NPS) that supports the procedure with its patented flow reversal technology.
The company further states in its recent release that, compared to traditional open surgery (carotid endarterectomy [CEA]), TCAR has demonstrated a lower risk of acute heart attack, fewer occurrences of nerve injury, shorter time required to perform the procedure, and a reduced length of stay at the hospital for patients.
“Completing the 100,000th TCAR procedure is the culmination of more than 15 years’ worth of work by members of the Silk Road Medical team and the healthcare providers we work with,” said Chas McKhann, chief executive officer of Silk Road. “As we celebrate this important milestone, we remain excited and motivated to establish TCAR as the standard of care for addressing carotid artery disease.”
